U.S. Central Venous Catheter Market to Surpass US$ 1,332.2 Million by 2026 - Coherent Market Insights

U.S. Central Venous Catheter Market, by Product Type (Peripherally Inserted Central Catheters (PICC), Implantable Ports, Tunneled Central Venous Catheter, and Non-tunneled Central Venous Catheter), by Design (Single Lumen, Double Lumen, and Multi Lumen), by Composition (Polyurethane, Polyethylene, and Silicon), by Procedure (Cardiovascular Procedure, Chemotherapy Procedure, and Dialysis Procedure), and by End User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics) was valued at US$ 825.9 million in 2018, and is projected to exhibit a CAGR of 6.2% over the forecast period (2018 – 2026).

Increasing prevalence of renal diseases and cancer is expected to augment the market growth Increasing prevalence of diseases that require long-term therapies such as cancer (chemotherapy) and end stage renal disease (dialysis) is expected to fuel growth of the U.S. central venous catheter market. According to the National Center for Chronic Disease Prevention and Health Promotion, 2017, around 30 million people or 15% of the U.S. adults were estimated to have chronic kidney. According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012. Furthermore, WHO stated that the number of new cases is expected to rise by around 70% by 2030. Also, in 2015, cancer was responsible for 8.8 million deaths globally

Browse 38 Market Data Tables and 34 Figures spread through 117 Pages and in-depth TOC on ‘U.S. Central Venous Catheter Market - U.S. Forecast to 2026, by Product Type (Peripherally Inserted Central Catheters (PICC), Implantable Ports, Tunneled Central Venous Catheter, and Non-tunneled Central Venous Catheter), by Design (Single Lumen, Double Lumen, and Multi Lumen), by Composition (Polyurethane, Polyethylene, and Silicon), by Procedure (Cardiovascular Procedure, Chemotherapy Procedure, and Dialysis Procedure), and by End User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics)  

To know the latest trends and insights prevalent in the Central Venous Catheter Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-central-venous-catheter-market-2610

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance in July 2018, B. Braun Melsungen AG acquired bloodlines business of NxStage Medical, Inc. Similarly, in 2017, Becton, Dickinson, and Company acquired C.R. Bard, Inc. which created a new health care industry leader with approximately US$16 billion in annualized revenue

Key Takeaways of the Central Venous Catheter Market:

• The U.S. central venous catheter market is expected to exhibit a CAGR of 6.2% over the forecast period, owing to increasing prevalence of cancer
• Among product type, the peripherally inserted central catheters (PICC) segment held a dominant position in the Central Venous Catheter Market in 2018, owing to high commercially availability of peripherally inserted central catheters
• Among designs, the multi lumen segment held a dominant position in the Central Venous Catheter Market in 2018, owing to high adaption of multi lumen catheters
• Among compositions, the polyurethane segment held a dominant position in the Central Venous Catheter Market in 2018, due to properties of polyurethane such as toughness, thinner lumen walls, and larger internal diameter
• Among procedures, the chemotherapy procedure segment held a dominant position in the Central Venous Catheter Market in 2018, owing to high prevalence of cancer
• Key players operating in the S. central venous catheter market include, Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, Waisman Biomanufacturing, AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics Corporation